TOP - June 2011, Vol 4, No 4
This past April, Mountain States Health Alliance’s Regional Cancer Center celebrated the 1-year anniversary of its new, state-of-theart oncology pharmacy. Located in the Regional Cancer Center’s dedicated medical oncology facility, the pharmacy provides USP <797>-compliant chemotherapy and supportive care agents as well as the benefit of face-to-face collaboration between pharmacists and the rest of the cancer care team.
Pharmacogenomics is the study of the role of inherited and acquired genetic variation in drug response.1 A focus of research in recent years on genome-wide association studies ultimately may help identify patient- and/or cancer-specific biomarkers that will facilitate optimization of drug therapy including guiding drug selection, dose, and treatment duration.2 The identification of the role of KRASmutations in select patients with colorectal cancer (CRC) who are candidates for epidermal growth factor receptor (EGFR) in hibitors is one example of the clinical a
SALT LAKE CITY—Identifying safety measures for patients receiving oral chemotherapy is of the upmost importance, according to a presentation at the annual meeting of the Hematology/Oncology Pharmacy Association. This includes monitoring the administration of and adherence to the treatment as well as ensuring the prevention of any medication errors.
SALT LAKE CITY—Early identification of nutrition status and treatmentrelated nutrition risk are important steps in the continuum of care for cancer patients, according to an oral presentation at the annual meeting of the Hematology/Oncology Pharmacy Association.
SALT LAKE CITY—Choosing appropriate treatment options and then following strict monitoring parameters are essential for patients with challenging cancer pain, according to a presentation at the annual meeting of the Hematology/Oncology Pharmacy Association.
“Cancer patients with pain have risks too. So risk stratification and risk minimization should be employed for all patients,” said David S. Craig, PharmD, BCPS, from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.
SALT LAKE CITY—Although radiation- induced toxicities are common in an outpatient setting, several treatment options have proven very successful—as long as the appropriate monitoring parameters are in place, according to a presentation at the annual meeting of the Hematology/Oncology Pharmacy Association by Makala Pace, PharmD, BCOP, clinical pharmacy specialist at The University of Texas M. D. Anderson Cancer Center in Houston.
SALT LAKE CITY—Reliable tests are sorely needed to help determine the best dose regimen before chemotherapy to minimize toxicities for patients with metastatic colon cancer, according to a talk given at the annual meeting of the Hematology/Oncology Pharmacy Association.
SALT LAKE CITY—Although it’s important to strive for no chemotherapy-related medication errors, it’s just as important to have an organized system in place to identify, report, and manage these errors when they occur, according to a presentation at the annual meet ing of the Hematology/Oncology Pharmacy Association.
SALT LAKE CITY—Bisphosphonates may have a role as an adjuvant breast cancer treatment, cisplatin-based neoadjuvant chemotherapy should be considered for treating bladder cancer, and dose-dense chemotherapy may add benefit for patients with pediatric Ewing sarcoma, according to 3 presentations at the “Controversies in Care” session at the annual meeting of the Hematology/Oncology Pharmacy Association.
Bisphosphonates in Breast Cancer
The Oncology Pharmacist congratulates Lindsay Kaster, PharmD, for being chosen by more than 750 of her peers as this year’s T.O.P. Pharmacist award winner.
Results 1 - 10 of 13